[1] |
Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a meview[J]. JAMA, 2022, 327:464-477. doi:10.1001/jama.2022.0003.
|
[2] |
Minnie SA, Hill GR. Immunotherapy of multiple myeloma[J]. J Clin Invest, 2020, 130:1565-1575. doi:10.1172/JCI129205.
|
[3] |
Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches[J]. Leukemia, 2020, 34:985-1005. doi:10.1038/s41375-020-0734-z.
|
[4] |
Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice[J]. CA Cancer J Clin, 2023,73:275-285. doi:10.3322/caac.21771.
|
[5] |
Shao M, Yu Q, Teng X, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase Ⅰ/Ⅱ clinical trial[J]. Bone Marrow Transplant, 2021,56:1642-1650.doi:10.1038/s41409-021-01226-9.
|
[6] |
Zhou X, Rasche L, Kortüm KM, et al. Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies[J]. Front Immunol, 2020, 11:620312. doi:10.3389/fimmu.2020.620312.
|
[7] |
Azoulay É, Castro P, Maamar A, et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study[J]. Lancet Haematol, 2021,8:e355-e364. doi:10.1016/S2352-3026(21)00060-0.
|
[8] |
Mensurado S, Blanco-Domínguez R, Silva-Santos B. The emerging roles of γδ T cells in cancer immunotherapy[J]. Nat Rev Clin Oncol, 2023,20:178-191. doi:10.1038/s41571-022-00722-1.
|
[9] |
Oden F, Marino SF, Brand J, et al. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma[J]. Mol Oncol, 2015,9:1348-1358. doi:10.1016/j.molonc.2015.03.010.
|
[10] |
Raverdeau M, Cunningham SP, Harmon C, et al. γδ T cells in cancer: a small population iof lymphocytes with big implications[J]. Clin Transl Immunology, 2019, 8:e01080.doi:10.1002/cti2.1080.
|
[11] |
Xu Y, Xiang Z, Alnaggar M, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer[J]. Cell Mol Immunol, 2021, 18:427-439. doi:10.1038/s41423-020-0515-7.
|
[12] |
Hu Y, Hu Q, Li Y, et al. γδ T cells: origin and fate, subsets, diseases and immunotherapy[J]. Signal Trans-duct Target Ther, 2023, 8:434. doi:10.1038/s41392-023-01653-8.
|